UMB Bank n.a. Has $94,000 Stock Position in Illumina, Inc. (NASDAQ:ILMN)

UMB Bank n.a. lowered its stake in Illumina, Inc. (NASDAQ:ILMN) by 57.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 706 shares of the life sciences company’s stock after selling 953 shares during the quarter. UMB Bank n.a.’s holdings in Illumina were worth $94,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of ILMN. Intech Investment Management LLC acquired a new stake in shares of Illumina during the second quarter valued at approximately $313,000. Sei Investments Co. raised its stake in Illumina by 37.3% during the 2nd quarter. Sei Investments Co. now owns 97,681 shares of the life sciences company’s stock valued at $10,196,000 after purchasing an additional 26,538 shares during the period. Thrivent Financial for Lutherans lifted its holdings in shares of Illumina by 97.1% in the second quarter. Thrivent Financial for Lutherans now owns 60,298 shares of the life sciences company’s stock valued at $6,294,000 after purchasing an additional 29,709 shares in the last quarter. Gabelli Funds LLC boosted its position in shares of Illumina by 27.6% in the second quarter. Gabelli Funds LLC now owns 6,589 shares of the life sciences company’s stock worth $688,000 after buying an additional 1,425 shares during the period. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Illumina by 127.6% during the second quarter. EverSource Wealth Advisors LLC now owns 776 shares of the life sciences company’s stock valued at $81,000 after buying an additional 435 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Price Performance

Shares of Illumina stock opened at $134.76 on Friday. Illumina, Inc. has a 1-year low of $100.08 and a 1-year high of $156.66. The firm has a fifty day simple moving average of $139.06 and a 200-day simple moving average of $134.26. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The stock has a market capitalization of $21.37 billion, a price-to-earnings ratio of -13.53 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.33 earnings per share. On average, sell-side analysts expect that Illumina, Inc. will post 4.13 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Canaccord Genuity Group increased their price objective on Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a research note on Tuesday, November 5th. Morgan Stanley decreased their price target on shares of Illumina from $156.00 to $150.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Leerink Partners boosted their price objective on shares of Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and cut their target price for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Finally, UBS Group boosted their price target on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Eight equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $165.63.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.